📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Cingulate

1.1 - Company Overview

Cingulate Logo

Cingulate

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of precision timed-release therapeutics combining delivery technology with proven medications to deliver rapid-onset, once-daily, full-day efficacy. Portfolio includes ADHD treatments CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), and CTx-2103 (buspirone HCl) for anxiety under development, powered by its Precision Timed Release (PTR) platform enabling predefined release times.

Products and services

  • Precision Timed Release Platform Technology (PTR): Architects a custom-engineered drug delivery platform enabling precise, predefined release times and potential multi-active formulations, creating unmatched release profiles for proven medications
  • CTx-1301: Engineers a clinical-grade dexmethylphenidate-based ADHD medication designed for once-daily dosing, delivering rapid onset and full-day efficacy to treat attention-deficit/hyperactivity disorder
  • CTx-1302: Produces a pharmaceutical-grade dextroamphetamine-based ADHD medication offering once-daily dosing with quick onset and sustained effectiveness across the day for attention-deficit/hyperactivity disorder treatment

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Cingulate

Mitokinin Logo

Mitokinin

HQ: United States Website
  • Description: Provider of biotechnology R&D focused on medicinal chemistry to generate kinetin analogs optimized for activating PINK1, with plans to develop these analogs or optimized variants to treat Parkinson's disease.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Mitokinin company profile →
Gabather Logo

Gabather

HQ: Sweden Website
  • Description: Provider of research and development of innovative therapeutics for neuropsychiatric disorders, focusing on pro-cognitive drug candidates targeting GABAA receptor systems for central nervous system disorders, including GT-002, a small-molecule GABAA receptor PAM in clinical development to improve learning and memory, reduce anxiety, and promote social interaction.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Gabather company profile →
Hypnion Logo

Hypnion

HQ: United States Website
  • Description: Provider of neuroscience drug discovery and development services focused on novel therapeutics for central nervous system disorders, including sleep and wake-alertness disorders and circadian rhythm abnormalities; offers SCORE-2004, a drug discovery platform.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Hypnion company profile →
Lobe Sciences Logo

Lobe Sciences

HQ: Canada Website
  • Description: Provider of life sciences focused on transformational medicine.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Lobe Sciences company profile →
Semnur Pharma Logo

Semnur Pharma

HQ: United States Website
  • Description: Provider of specialty pharmaceutical development focused on the clinical and commercial advancement of innovative products for pain management, including SP-102 (SEMDEXA), a non-opioid injectable corticosteroid gel designed to treat moderate to severe chronic radicular pain/sciatica via epidural injection.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Semnur Pharma company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Cingulate

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Cingulate

2.2 - Growth funds investing in similar companies to Cingulate

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Cingulate

4.2 - Public trading comparable groups for Cingulate

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Cingulate

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Cingulate

What does Cingulate do?

Cingulate is a provider of precision timed-release therapeutics combining delivery technology with proven medications to deliver rapid-onset, once-daily, full-day efficacy. Portfolio includes ADHD treatments CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), and CTx-2103 (buspirone HCl) for anxiety under development, powered by its Precision Timed Release (PTR) platform enabling predefined release times.

Who are Cingulate's competitors?

Cingulate's competitors and similar companies include Mitokinin, Gabather, Hypnion, Lobe Sciences, and Semnur Pharma.

Where is Cingulate headquartered?

Cingulate is headquartered in United States.

How many employees does Cingulate have?

Cingulate has 1,000 employees 🔒.

When was Cingulate founded?

Cingulate was founded in 2010 🔒.

What sector and industry vertical is Cingulate in?

Cingulate is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Cingulate

Who are the top strategic acquirers in Cingulate's sector and industry

Top strategic M&A buyers and acquirers in Cingulate's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Cingulate?

Top strategic M&A buyers groups and sectors for Cingulate include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Cingulate's sector and industry vertical

Which are the top PE firms investing in Cingulate's sector and industry vertical?

Top PE firms investing in Cingulate's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Cingulate's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Cingulate's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Cingulate's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Cingulate include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Cingulate's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Cingulate?

The key public trading comparables and valuation benchmarks for Cingulate include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Cingulate for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Cingulate with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Cingulate's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Cingulate with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Cingulate's' sector and industry vertical?

Access recent funding rounds and capital raises in Cingulate's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Cingulate